Comparison of Serum Gamma Glutamyl Transferase Levels between Prostate Cancer Patients and Their Healthy Peers.
Biomarker
Gamma glutamyl transferase
Prostate cancer
Prostate specific antigen
Journal
Iranian journal of public health
ISSN: 2251-6093
Titre abrégé: Iran J Public Health
Pays: Iran
ID NLM: 7505531
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
17
04
2022
accepted:
18
08
2022
medline:
18
8
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
ppublish
Résumé
Prostate cancer (PCa) is the most common cancer affecting men, apart from cutaneous cancers. Serum prostate specific antigen (PSA) levels are frequently used to predict prostate cancer diagnosis. However, many causes (e.g., prostatitis, benign prostate obstruction, urethral catheterization) may cause elevated PSA, in addition to PCa. We aimed to investigate the gamma glutamyl transferase (GGT) levels, a serum biomarker not affected by situations other than cancer causing elevated PSA. The study evaluated male patients with prostate biopsy due to high serum PSA levels and/or abnormal digital rectal examination (DRE) examined in Ordu University Education and Research Hospital, Ordu/Turkey urology clinic from April 2019 to April 2021. The patient group in the study included 261 men with PCa diagnosis and the control group included 245 healthy men with normal PSA levels, and no PCa and/or benign prostate obstruction (BPO). The two groups were compared in terms of serum GGT levels. GGT was significantly low in the PCa group and might be a predictor in terms of PCa ( Serum GGT levels might assist in diagnosis of PCa. However, diagnostic power is weak due to low specificity. There is a need for studies investigating the efficacy of GGT levels for prediction of PCa diagnosis and assessing other parameters alongside GGT.
Sections du résumé
Background
UNASSIGNED
Prostate cancer (PCa) is the most common cancer affecting men, apart from cutaneous cancers. Serum prostate specific antigen (PSA) levels are frequently used to predict prostate cancer diagnosis. However, many causes (e.g., prostatitis, benign prostate obstruction, urethral catheterization) may cause elevated PSA, in addition to PCa. We aimed to investigate the gamma glutamyl transferase (GGT) levels, a serum biomarker not affected by situations other than cancer causing elevated PSA.
Methods
UNASSIGNED
The study evaluated male patients with prostate biopsy due to high serum PSA levels and/or abnormal digital rectal examination (DRE) examined in Ordu University Education and Research Hospital, Ordu/Turkey urology clinic from April 2019 to April 2021. The patient group in the study included 261 men with PCa diagnosis and the control group included 245 healthy men with normal PSA levels, and no PCa and/or benign prostate obstruction (BPO). The two groups were compared in terms of serum GGT levels.
Results
UNASSIGNED
GGT was significantly low in the PCa group and might be a predictor in terms of PCa (
Conclusion
UNASSIGNED
Serum GGT levels might assist in diagnosis of PCa. However, diagnostic power is weak due to low specificity. There is a need for studies investigating the efficacy of GGT levels for prediction of PCa diagnosis and assessing other parameters alongside GGT.
Identifiants
pubmed: 37593509
doi: 10.18502/ijph.v52i7.13251
pii: IJPH-52-1487
pmc: PMC10430399
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1487-1494Informations de copyright
Copyright © 2023 Yuce et al. Published by Tehran University of Medical Sciences.
Déclaration de conflit d'intérêts
Conflict of Interest The authors declare that there is no conflict of interest.
Références
Cent European J Urol. 2018;71(2):242-247
pubmed: 30038817
Angew Chem Int Ed Engl. 2018 Sep 24;57(39):12780-12784
pubmed: 30025197
FASEB J. 1997 Apr;11(5):374-5
pubmed: 9141504
Annu Rev Biochem. 1976;45:559-604
pubmed: 9027
BMC Cancer. 2018 Feb 20;18(1):205
pubmed: 29463235
Int J Cancer. 2017 Feb 15;140(4):818-824
pubmed: 27861848
Methods Enzymol. 2005;401:484-501
pubmed: 16399404
Mod Pathol. 1997 Jan;10(1):1-6
pubmed: 9021720
Anticancer Res. 2019 Oct;39(10):5773-5780
pubmed: 31570481
Hum Pathol. 1999 Mar;30(3):300-5
pubmed: 10088549
Crit Rev Clin Lab Sci. 2001 Aug;38(4):263-355
pubmed: 11563810
Turk J Urol. 2014 Jun;40(2):82-8
pubmed: 26328156
Urology. 2007 Oct;70(4):743-7
pubmed: 17991548
Eur Urol. 2014 Oct;66(4):619-22
pubmed: 25012523
Biomed Res Int. 2015;2015:853573
pubmed: 26682223
J Urol. 2004 Feb;171(2 Pt 2):S36-40
pubmed: 14713751
Int J Oncol. 2003 Jan;22(1):5-13
pubmed: 12469179
Clin Biochem. 1990 Apr;23(2):105-12
pubmed: 1973646
Int Braz J Urol. 2018 Jul-Aug;44(4):704-708
pubmed: 29570262
Mutat Res. 1988 Mar;195(2):137-49
pubmed: 3277035
Biochem Pharmacol. 1997 Apr 4;53(7):987-93
pubmed: 9174112
Int J Prev Med. 2011 Jan;2(1):28-31
pubmed: 21448402
Cancer. 1976 Apr;37(4):1800-7
pubmed: 4219
Urology. 2001 Apr;57(4 Suppl 1):90-4
pubmed: 11295603
Anticancer Res. 1996 Sep-Oct;16(5B):3053-8
pubmed: 8920766
Eur J Cancer. 2011 Sep;47(13):2033-41
pubmed: 21486691
BJU Int. 2005 May;95(7):961-2
pubmed: 15839913
BMC Cancer. 2017 May 5;17(1):316
pubmed: 28476099
Kaohsiung J Med Sci. 2017 Nov;33(11):572-577
pubmed: 29050675
Toxicol Appl Pharmacol. 1992 May;114(1):56-62
pubmed: 1350117